Nephrology Times
Advertisement
The FDA has requested comments to help shape the development of a program assessing chemicals in food post-market.
Carla Nester spoke about two presentations at Kidney Week focused on potential therapies for C3 glomerulopathy.
Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?
Researchers compared incidence of mortality and kidney failure between patients with CKD and rare kidney diseases.
Sagar Nigwekar discussed interim data from the SEAPORT 1 trial of INZ-701 for treatment of calciphylaxis.
Jesse Goodrich and Hailey Hampson spoke about their study of the connection between PFAS, the gut, and kidney function.
Guru Reddy discussed three posters presented by Unicycive Therapeutics at ASN Kidney Week 2024, on UNI-494 and OLC.
Benefits of empagliflozin continued for a period after discontinuation but were lesser and seemed temporary.
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
Nephrology experts at Loma Linda University School of Medicine will host the Rare Kidney Disease Conference December 7-8.
BTK inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with membranous nephropathy.
The FDA recalled a batch of Dr. Reddy’s Cinacalcet Tablets, a treatment for chronic kidney disease (CKD).
Susan Quaggin, winner of the 2024 John P. Peters Award, spoke with us about the award, her work, and ASN Kidney Week.
ApEx Pāthshālā, the Apex Nephrology Board Review Course, will take place December 6-8, 2024, in Mumbai, India.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
The Lupus Foundation of America will honor Brad H. Rovin, MD, and Alí Duarte-García, MD, at the Evelyn V. Hess Reception.
Melissa Little discussed kidney regeneration and her stem cell research with Joel Topf of Nephrology Times.
Finerenone did not modify kidney outcomes but reduced albuminuria and risk of new-onset macroalbuminuria in patients with HF.
Mohamad Hussain spoke with us about a phase 3 trial of the acellular tissue engineered vessel in AV access for hemodialysis.
CMS issued a final rule on the ESRD Prospective Payment System, which will raise payment rates and cover oral-only drugs.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.